Publications by authors named "Fengyan Jin"

Claim this Profile
C
Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study.
Dong Liang, Yurong Yan, Shenrui Bai, Weiling Xu, Qiaoli Wang, Fengyan Jin

Ann Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TMSCl-Promoted Cascade Sulfonylation/Cyclization of Indole-Linked Propargylic Alcohols with Sodium Sulfinates for the Construction of Sulfonylated Indeno[1,2-]indoles.
Meng Liang, Miaohao Dong, Ruchun Yang, Lin Lu, Fengyan Jin

J Org Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood aging: From definition and mechanisms to clinical practice.
Qiliang Yin, Yan Zhang, Xingcheng Yi, Jian Li, Yun Dai, Fengyan Jin

Mech Ageing Dev· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NIS-Promoted Cascade Electrophilic Spirocyclization of Aryl Alkyne-Tethered Indoles to Construct Iodinated Spiroindolenines.
Xingyue Wang, Meng Liang, Jiang Bai, Ruchun Yang, Fengyan Jin

J Org Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an artificial intelligence-based early diagnostic system for light-chain amyloidosis.
Wei Yan, Jian Chen, Tao He, Haoze Xu, Jianmin Chen, Fengyan Jin

Ann Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study.
Dong Liang, Yurong Yan, Qiaoli Wang, Shenrui Bai, Weiling Xu, Fengyan Jin

Hematol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a prognostic staging system for primary plasma cell leukemia.
Mengru Tian, Gang An, Weijun Fu, Wenqiang Yan, Lu Li, Fengyan Jin

J Hematol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma.
Tingting Yue, Yue Sun, Yun Dai, Fengyan Jin

Blood Rev· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CLO25-072: A Multicenter, Randomized, Controlled, Non-Inferiority Study of Narlumosbart Compared With Denosumab in the Treatment of Bone Disease in Patients With Multiple Myeloma.
Honghui Huang, Fei Li, Yan Xu, Wenming Chen, Guangxun Gao, Fengyan Jin

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissecting the high-risk property of 1q gain/amplification in patients with newly diagnosed multiple myeloma.
Xinyue Liang, Weiling Xu, Fan Zhou, Wenyang Huang, Xingcheng Yi, Jingxuan Wang, Fengyan Jin

Am J Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arterial specification precedes microvascular restitution in the peri-infarct cortex that is driven by small microvessels.
Nina Hagemann, Yachao Qi, Ayan Mohamud Yusuf, AnRan Li, Xiaoni Zhang, Fengyan Jin

J Cereb Blood Flow Metab· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent presentation of proliferative glomerulonephritis with monoclonal immunoglobulin deposits and light chain proximal tubulopathy: a case report and review of the literature.
Jingdong Zhang, Yang Liu, Fengyan Jin, Jia Li, Hui Wang, Jinyu Yu

Front Med (Lausanne)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study.
Xincheng Jiang, Xiaoyan Han, Fengyan Jin, Gang An, Jian Hou, Jingsong He

Hematology· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study.
Dong Liang, Yurong Yan, Shenrui Bai, Weiling Xu, Qiaoli Wang, Fengyan Jin

BMC Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis.
Weiling Xu, Xinyue Liang, Shanshan Liu, Xingcheng Yi, Mengru Tian, Jingxuan Wang, Fengyan Jin

Clin Med (Lond)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic frailty-tailored therapy (DynaFiT): A proof-of-concept study in elderly patients with newly diagnosed multiple myeloma.
Yun Dai, Fengyan Jin

Blood Sci· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study.
Yingjie Zhang, Xinyue Liang, Weiling Xu, Xingcheng Yi, Rui Hu, Jingxuan Wang, Fengyan Jin

J Hematol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tislelizumab and radiation therapy in low-risk early-stage extranodal natural killer/T-cell lymphoma, nasal type: a phase II study protocol.
Jia-Ying Li, Shu-Nan Qi, Chen Hu, Xin Liu, Yong Yang, Feng-Yan Jin

Future Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LncRNAs-circRNAs as Rising Epigenetic Binary Superstars in Regulating Lipid Metabolic Reprogramming of Cancers.
Shanshan Liu, Benzheng Jiao, Hongguang Zhao, Xinyue Liang, Fengyan Jin

Adv Sci (Weinh)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma.
Mengru Tian, Xinyue Liang, Weiling Xu, Xingcheng Yi, Tingting Yue, Jingxuan Wang, Fengyan Jin

Ann Hematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma.
Shanshan Liu, Hongwei Zhou, Weiling Xu, Tao Jin, Xinyue Liang, Fengyan Jin

Ann Hematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The R2-ISS in a Multicenter Cohort of Chinese Patients With Newly Diagnosed Multiple Myeloma.
Peiyu Yang, Fan Zhou, Yujun Dong, Guangxun Gao, Hua Xue, Fengyan Jin

Hemasphere· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma.
Peiyu Yang, Weiling Xu, Xinyue Liang, Shanshan Yu, Xingcheng Yi, Jingxuan Wang, Fengyan Jin

Am J Hematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct Synthesis of Benzo[]fluorenyl Thiophosphates via Tandem Cyclization of Diynols with (RO)P(O)SH.
Sha Du, Shimin Jiang, Ruchun Yang, Fengyan Jin, Haiyang Huang

Org Lett· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma.
Peiyu Yang, Haimin Chen, Xinyue Liang, Weiling Xu, Shanshan Yu, Fengyan Jin

Am J Hematol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis